United States Patent 11,969,414: Scope, Claims, and US Patent Landscape for Ripretinib Plus Itraconazole Concurrency
What does US 11,969,414 claim, in plain technical scope?
US 11,969,414 claims a specific drug-drug interaction management method for advanced gastrointestinal stromal tumor (GIST) using ripretinib while the patient concurrently takes itraconazole.
Claim 1 (as provided) scope elements
Claim 1 is structured around a single, tight therapeutic use plus a quantitative interaction outcome plus a monitoring requirement. The method requires all of the following:
- Patient condition / indication
- “A patient suffering from an advanced gastrointestinal stromal tumor”
- Concurrent medication
- Patient “is being treated concurrently itraconazole”
- Specific dosing regimen
- “orally administering” ripretinib at a 150 mg daily dose
- Quantified PK interaction result
- Concurrent itraconazole and ripretinib “increases ripretinib AUC0-inf by 99%”
- Compared to ripretinib “without concurrent treatment of itraconazole”
- Clinical consequence
- The patient is “at higher risk of an adverse event” due to the combination
- Consequence management
- “monitoring the patient for the adverse event due to the ripretinib and itraconazole administration”
Functional claim character
The claim is not limited to a particular adverse event type (e.g., only QT prolongation, only hepatotoxicity, only bleeding). It is limited to monitoring for an adverse event that is linked to ripretinib and itraconazole administration, and it anchors the necessity of monitoring to a specific magnitude of systemic exposure change (AUC0-inf +99%).
How narrow is the claim versus typical ripretinib labeling?
Claim 1 is narrower than broad “use of ripretinib” claims because it combines multiple constraining features:
- Disease state: “advanced” GIST (not just GIST broadly).
- Co-therapy: mandatory concurrent itraconazole.
- Dose: exact 150 mg daily ripretinib (not a range in the claim as presented).
- Quantitative PK threshold: +99% AUC0-inf increase (not a generic interaction statement).
- Outcome-linked clinical action: “monitoring” for adverse event risk attributable to the combination.
In practice, the claim reads like a conditional clinical protocol triggered by a known strong CYP/P-gp interaction (itraconazole as a strong inhibitor) with a defined PK effect and a mandated monitoring step.
What is the likely legal meaning of “increases AUC0-inf by 99%”?
In US method claims like this, the “increases AUC0-inf by 99%” element operates as a required performance characteristic of the treatment scenario.
For infringement, a challenger typically attacks either:
- whether the regimen in the accused method meets the PK effect requirement as claimed, or
- whether the PK effect is measured/established in the relevant population under the relevant conditions (dose, route, concurrency timing, and itraconazole regimen).
Your claim language, however, is framed as an objective comparative PK result:
- ripretinib + itraconazole yields AUC0-inf that is 99% higher than ripretinib without itraconazole.
That makes the quantitative element central to both claim construction and validity arguments (if prior art shows different magnitude or relies on a different co-medication/dose).
What is the likely patent landscape around this claim type?
Claim archetype: DDI management method claims
The claim is in the family of US patents that attempt to capture:
- a specific drug-drug interaction (DDI),
- expressed through PK metrics (AUC0-inf),
- tied to clinical risk, and
- coupled to a monitoring or dose-adjustment instruction.
This style often overlaps with:
- label-based warnings,
- interaction studies,
- and prior generic “monitoring” method claims.
The novelty angle, when a DDI has known mechanism, typically becomes the combination of:
- specific drugs,
- specific dose,
- specific magnitude of exposure change, and
- specific clinical monitoring instruction.
Where the landscape commonly sits
For ripretinib, the US landscape generally falls into these buckets:
- Core composition and use patents for ripretinib (structure, solid forms, salts, polymorphs, synthesis, dosing regimens).
- Regimen and indication patents for advanced GIST and specific lines of therapy.
- Dose and PK / exposure-response patents.
- Drug-drug interaction patents for coadministration with inhibitors/inducers relevant to ripretinib metabolism and transport.
This particular claim sits in the intersection of:
- ripretinib PK exposure management and
- concurrent antifungal strong inhibitor (itraconazole) management.
What does this mean for freedom-to-operate (FTO) in the US?
Highest-risk implementation scenario
FTO exposure is highest if an accused practice:
- treats advanced GIST,
- gives ripretinib 150 mg orally once daily (or as your claim implies daily),
- while the patient is on itraconazole concurrently, and
- includes a method that amounts to “monitoring” for an adverse event risk caused by the combination.
Even if monitoring is routine in oncology practice, this claim is still a method claim that can be practiced during routine care if all elements are satisfied.
Lower-risk implementation scenario
FTO risk drops if any required element is absent, including:
- switching from itraconazole to a different antifungal,
- using a different ripretinib dose than 150 mg daily,
- avoiding concurrent itraconazole,
- or administering with no “concurrent” presence as understood for the claim’s performance comparison.
Because the claim includes an AUC0-inf +99% constraint, risk also depends on whether the accused regimen produces that PK magnitude under the relevant conditions.
What are the key claim-interpretation pressure points?
Based on the claim text, the likely pressure points in US litigation or PTAB proceedings are:
- “Advanced gastrointestinal stromal tumor”
- whether “advanced” is a clinical staging term in the record or a label/diagnosis-based descriptor.
- “Concurrently itraconazole”
- whether concurrency requires ongoing itraconazole dosing during the ripretinib course, and whether timing matters.
- “150 mg daily dose”
- whether the accused regimen matches exactly that dose and schedule.
- “AUC0-inf increases by 99%”
- whether infringement requires that exact quantitative outcome, or whether substantial approximation could be argued (depends on construction and how courts treat quantitative PK limitations).
- “Monitoring the patient for the adverse event”
- what qualifies as “monitoring” in practice, and whether routine adverse event surveillance suffices if it addresses the claimed risk category.
How to map this claim into adjacent US patent buckets (competitive and legal analysis)
Even without additional claim set details (dependent claims, definitions, priority chain, or prosecution history), the claim’s combination can be mapped into a structured landscape view:
A. Ripretinib core patents (likely upstream)
These usually cover:
- the compound and related analogs,
- solid forms and manufacturing,
- initial dosing/efficacy regimens.
Effect on 11,969,414: upstream patents usually establish baseline ripretinib exclusivity. The incremental novelty of 11,969,414 is the specific DDI management for itraconazole.
B. Indication and regimen patents (likely adjacent)
These usually cover:
- treatment of GIST, including advanced disease,
- line-of-therapy positioning,
- dosing schedules.
Effect on 11,969,414: this claim narrows the regimen by adding itraconazole concurrency, dose, quantitative AUC change, and monitoring.
C. Drug-drug interaction patents (direct competitive field)
These often cover:
- coadministration with CYP/P-gp inhibitors (azole antifungals, macrolides, some antivirals),
- coadministration with inducers (rifampin, certain anticonvulsants),
- PK metrics (AUC, Cmax, half-life),
- management steps (dose modifications, avoidance lists, monitoring).
Effect on 11,969,414: it is a DDI-specific method tied to a quantified magnitude of exposure increase and a clinical monitoring step.
What would constitute the closest prior art (analysis-ready)?
The closest prior art to challenge scope or novelty would typically include:
- PK interaction studies showing itraconazole increases ripretinib exposure.
- Clinical pharmacology documents or publications that provide:
- an exposure comparison metric for the ripretinib + itraconazole combination,
- a dose-matched condition (or close),
- and patient monitoring guidance tied to exposure increases.
Because your provided claim requires a +99% AUC0-inf outcome, prior art that reports a different percent change or uses different dosing conditions would be a potential distinction.
Because your claim requires “advanced GIST,” prior art that focuses only on PK in healthy volunteers could still be relevant for anticipation/obviousness arguments if the PK interaction is the same and if the method’s therapeutic context does not add a new technical feature.
Practical enforcement implications for 11,969,414
A method claim like this can be enforced against:
- manufacturers promoting a labeled or off-label coadministration protocol,
- providers or institutions where the method steps are used as part of practice,
- and entities training clinicians where the training amounts to a “use” or “induced” practice.
The enforcement value depends heavily on:
- whether the field practice includes itraconazole as a common concurrent antifungal,
- whether clinicians treat advanced GIST patients with ripretinib 150 mg daily concurrently with itraconazole,
- and whether adverse-event monitoring includes the “due to” risk framing in the claim.
Key Takeaways
- US 11,969,414 claim 1 is a narrow drug-drug interaction management method for advanced GIST using ripretinib at 150 mg daily during concurrent itraconazole, with a defined quantitative PK result (ripretinib AUC0-inf +99%) and mandatory patient monitoring for adverse-event risk.
- The main scope constraints are (i) advanced GIST, (ii) itraconazole concurrency, (iii) exact ripretinib dose, (iv) the +99% AUC0-inf requirement, and (v) monitoring for adverse events caused by the combination.
- In the US landscape, this claim sits in the DDI method claim bucket and overlaps with patents/publications covering itraconazole as a strong inhibitor and PK exposure increases, but its enforceability hinges on the specificity of dose and quantitative PK effect.
FAQs
1. Does claim 1 require a particular adverse event type?
No. The claim requires monitoring for “the adverse event due to the ripretinib and itraconazole administration,” without specifying a named adverse event.
2. Is the quantitative PK element likely essential for infringement?
Yes. The claim includes “AUC0-inf increases by 99%,” which is a limiting feature and typically must be satisfied by the accused scenario.
3. What patient context does the claim require?
The patient must suffer from advanced gastrointestinal stromal tumor.
4. If itraconazole is stopped before ripretinib starts, does the claim apply?
The claim requires “concurrently itraconazole,” so removing concurrency would be expected to avoid one of the required elements.
5. How does this claim differ from general ripretinib dosing claims?
It adds a specific DDI with itraconazole, an exact 150 mg daily dose, a defined exposure increase (+99% AUC0-inf), and a monitoring method.
References
No sources were provided and no document text for US 11,969,414 beyond the single claim you supplied is available in the prompt.
